U.S. labs began monitoring new coronaviruses this week.

Six U.S. public health laboratories plan to begin monitoring the general population of the new coronavirus this week,media reported. The U.S. Centers for Disease Control and Prevention (CDC) says the risk of contracting the virus remains low for the general population. However, activating the disease surveillance network will enable the CDC and other public health officials to spread any virus throughout the country that has not been detected.

U.S. labs began monitoring new coronaviruses this week.

The six labs are located in San Francisco, Los Angeles, Seattle, Chicago and New York City, all of which are part of the U.S. influenza surveillance network and regularly monitor all types of viruses. In the laboratory, a general understanding of the extent to which various diseases spread in the community by detecting various pathogens in patient samples

Monitoring has not yet begun, in part because of problems with the cdc’s development of new coronavirus detection. The test will be used to monitor people who are suffering from symptoms caused by the COVID-19 virus. Last week, it was distributed to public health laboratories across the country, but most of them have been working on them. In response, the CDC said this usually occurs during the introduction of new tests, but it does not specify the cause of the error.

Peter Shult, director of infectious diseases at the Wisconsin Health Laboratory, one of the three major National Influenza Counseling Centers in the United States, said the existing system could start scanning new coronaviruses once testing began. “The measures we took during the 2009 H1N1 pandemic were to be able to use existing infrastructure to deal with new things when they emerge,” he said. Now we have more power and more experience in dealing with new events. “

In addition, clinical trial rooms in hospitals and other medical centers report data to the CDC. “It all provides a very broad picture of influenza activity,” Shult said.

That could mean there’s nothing there, or we just didn’t test it in the right area,” Shult said. “This is something we will have to work on in the coming months. “